Financière de Tubize SA EPS
Mi az Financière de Tubize SA EPS?
A EPS az Financière de Tubize SA - 5.85
Mi a EPS meghatározása?
Az egy részvényre jutó nyereség (EPS) az a társaság nyereségének a része, amely a törzsrészvények minden egyes fennálló részesedéséhez tartozik. A hígításhoz igazodik, és a tizenkét hónap után kiszámítjuk.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS a Health Care szektor a EURONEXT-on cégekben a Financière de Tubize SA -hoz képest
Mit csinál Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
eps -hoz hasonló cégek Financière de Tubize SA
- Jost's Engineering nak EPS 5.84 van
- Blue Star nak EPS 5.85 van
- Apollo Micro systems nak EPS 5.85 van
- Cambridge Technology Enterprises nak EPS 5.85 van
- AMGEN nak EPS 5.85 van
- WEX Inc nak EPS 5.85 van
- Financière de Tubize SA nak EPS 5.85 van
- Northern Oil and Gas nak EPS 5.86 van
- Stef S.A nak EPS 5.86 van
- Westlife Development nak EPS 5.86 van
- Northern Oil and Gas nak EPS 5.86 van
- J.B. Hunt Transport Services nak EPS 5.86 van
- e Crit SA nak EPS 5.86 van